Anti-thymocyte globulin as graft-
            <i>versus</i>
            -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Baron, Frédéric; Mohty, Mohamad; Blaise, Didier; Socié, Gèrard; Labopin, Myriam; Esteve, Jordi; Ciceri, Fabio; Giebel, Sebastian; Gorin, Norbert Claude; Savani, Bipin N.; Schmid, Christoph; Nagler, Arnon

doi:10.3324/haematol.2016.148510

Cited by 111 publications

(85 citation statements)

References 91 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 For SIB transplants, the recent randomized study would support the use of ATG-F at the dose of 30 mg/kg, 10 whereas retrospective studies would indicate a dose of thymoglobuline ranging from 2.5 to 5 mg/kg. 13 For matched UD transplants, the dose of ATG-F would be 60 mg/kg and the dose of thymoglobuline 4.5 to 7.5 mg/kg.…”

Section: Dose Of Atgmentioning

confidence: 99%

“…13 For matched UD transplants, the dose of ATG-F would be 60 mg/kg and the dose of thymoglobuline 4.5 to 7.5 mg/kg. [11][12][13][14] We have randomized thymoglobuline 7.5 vs 10 mg/kg for UD grafts, and have additional protection with the higher dose against severe aGVHD and extensive cGVHD, 15 but with no impact of NRM, relapse, and survival.…”

Section: Dose Of Atgmentioning

confidence: 99%

See 1 more Smart Citation

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point

Bacigalupo

2017

Blood Advances

View full text Add to dashboard Cite

Section: Dose Of Atgmentioning

confidence: 99%

Section: Dose Of Atgmentioning

confidence: 99%

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point

Bacigalupo

2017

Blood Advances

View full text Add to dashboard Cite

“…[16][17][18][19] A lower incidence of cGVHD after in vivo T-cell depletion confirms T-cell involvement, although higher rates of infections and relapse of underlying malignancy complicate this approach. 20,21 Host-reactive B cells are also associated with the development of cGVHD, 18 and rituximab provides clinical benefit; however, alloreactive B cells recur after treatment discontinuation. 22 Ibrutinib is a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK).…”

Section: Introductionmentioning

confidence: 99%

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Miklos

Cutler

Arora

et al. 2017

Blood

374

253

View full text Add to dashboard Cite

• Ibrutinib induced a high rate of sustained responses for patients with cGVHD and inadequate response to corticosteroid-containing therapy.• This trial supported the approval of ibrutinib for treatment of adult patients with cGVHD after failure of $1 lines of systemic therapy.Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic stem cell transplantation with few effective options available after failure of corticosteroids. B and T cells play a role in the pathophysiology of cGVHD. Ibrutinib inhibits Bruton tyrosine kinase in B cells and interleukin-2-inducible T-cell kinase in T cells. In preclinical models, ibrutinib reduced severity of cGVHD. This multicenter, open-label study evaluated the safety and efficacy of ibrutinib in patients with active cGVHD with inadequate response to corticosteroid-containing therapies. Forty-two patients who had failed 1 to 3 prior treatments received ibrutinib (420 mg) daily until cGVHD progression. The primary efficacy end point was cGVHD response based on 2005 National Institutes of Health criteria. At a median follow-up of 13.9 months, best overall response was 67%; 71% of responders showed a sustained response for ‡20 weeks. Responses were observed across involved organs evaluated. Most patients with multiple cGVHD organ involvement had a multiorgan response. Median corticosteroid dose in responders decreased from 0.29 mg/kg per day at baseline to 0.12 mg/kg per day at week 49; 5 responders discontinued corticosteroids. The most common adverse events were fatigue, diarrhea, muscle spasms, nausea, and bruising. Plasma levels of soluble factors associated with inflammation, fibrosis, and cGVHD significantly decreased over time with ibrutinib. Ibrutinib resulted in clinically meaningful responses with acceptable safety in patients with ‡1 prior treatments for cGVHD. Based on these results, ibrutinib was approved in the United States for treatment of adult patients with cGVHD after failure of 1 or more lines of systemic therapy. This trial was registered at www.clinicaltrials.gov as #NCT02195869. (Blood. 2017;130(21):2243-2250

show abstract

“…H. Green and E. Bell have pioneered the reconstituted living skin equivalent since the 1980s. Haematopoietic cells from bone marrow has saved the lives of a large number of patients with leukemia or lymphoma. Implantation of cardiomyocytes benefitted from phase III clinical trials and a consensus, established by the European Society of Cardiology, updated recommendations for the future of autologous cell therapy in the heart .…”

Section: The Body Is a “Cluster” Of Living Cells That Need A Duplex Cmentioning

confidence: 99%

Tackling the Concept of Symbiotic Implantable Medical Devices with Nanobiotechnologies

Alcaraz

Cinquin

Martin

2018

Biotechnology Journal

View full text Add to dashboard Cite

This review takes an approach to implanted medical devices that considers whether the intention of the implanted device is to have any communication of energy or materials with the body. The first part describes some specific examples of three different classes of implants, analyzed with regards to the type of signal sent to cells. Through several examples, the authors describe that a one way signaling to the body leads to encapsulation or degradation. In most cases, those phenomena do not lead to major problems. However, encapsulation or degradation are critical for new kinds of medical devices capable of duplex communication, which are defined in this review as symbiotic devices. The concept the authors propose is that implanted medical devices that need to be symbiotic with the body also need to be designed with an intended duplex communication of energy and materials with the body. This extends the definition of a biocompatible system to one that requires stable exchange of materials between the implanted device and the body. Having this novel concept in mind will guide research in a new field between medical implant and regenerative medicine to create actual symbiotic devices.

show abstract

Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Cited by 111 publications

References 91 publications

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Tackling the Concept of Symbiotic Implantable Medical Devices with Nanobiotechnologies

Contact Info

Product

Resources

About